AB Science: New Publication on Medrxiv Demonstrating Substantial Survival Benefits and Preserved Quality of Life with Masitinib in ALS Patients

Why It Matters

If validated, masitinib could become the first disease‑modifying ALS therapy that extends life without sacrificing quality, reshaping treatment standards and creating a sizable market opportunity.

Key Takeaways

• 5‑year survival reached 42.3% with masitinib, double historical rates.
• 52.9% survival in patients without prior total functional loss.
• Median overall survival 121 months vs 42‑month prediction, 79‑month gain.
• 49% of long‑term survivors kept independence, no ventilation or wheelchair.
• Early‑stage patients show strongest benefit, hinting at a treatable subpopulation.

Pulse Analysis

The new medRxiv analysis adds a compelling data point to the ALS therapeutic landscape, where few options exist beyond riluzole and edaravone. By targeting microglial and mast‑cell activity, masitinib appears to alter disease biology rather than merely slowing symptom progression. The reported 5‑year survival of 42.3%—and over 50% in patients treated before total functional loss—outperforms historical benchmarks that hover around 23%, suggesting a genuine survival advantage that could shift clinical practice if replicated in larger, peer‑reviewed trials.

Beyond raw survival numbers, the study highlights quality‑of‑life outcomes that matter to patients and caregivers. Nearly half of the long‑term survivors maintained independence, avoiding invasive support such as ventilation, gastrostomy, or wheelchair dependence. This dual benefit of longevity and preserved function addresses a critical gap in ALS care, where extended survival often comes at the cost of severe disability. The observation that benefits span diverse baseline prognostic groups points to a mechanistic effect tied to microglial inflammation, opening the door for biomarker‑driven patient selection.

AB Science’s upcoming phase 3 AB23005 trial, enrolling 408 patients with early‑stage disease, will test masitinib as an add‑on to riluzole. Success could secure regulatory approval in the United States and Europe, creating a first‑in‑class disease‑modifying option. Investors and industry watchers should monitor enrollment metrics, safety data, and any emerging companion diagnostics, as these factors will determine the drug’s commercial trajectory and its potential to reshape the ALS market, which currently represents an unmet need worth billions of dollars.